In a phase 2 trial of 186 adults with type 2 diabetes on metformin, once-daily oral zenagamtide 6, 25 or 50 mg lowered HbA1c by 0.9–1.4% at 36 weeks (differences vs placebo −0.5% to −1.09%). Gastrointestinal events rose with dose (26–47% vs 23% placebo).
RCTn = 186
Mora et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial